Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 5 of 5

Full-Text Articles in Pharmacoeconomics and Pharmaceutical Economics

Save The Pharmacy Piggy Bank: Managing Mega High-Cost Drugs, Richard K. Ogden Jr., Jerame Hill, Sam Abdelghany Dec 2018

Save The Pharmacy Piggy Bank: Managing Mega High-Cost Drugs, Richard K. Ogden Jr., Jerame Hill, Sam Abdelghany

Pharmacy Presentations

No abstract provided.


Save The Pharmacy Piggy Bank: Managing Mega High-Cost Drugs, Richard K. Ogden Jr., Jerame Hill, Sam Abdelghany Dec 2018

Save The Pharmacy Piggy Bank: Managing Mega High-Cost Drugs, Richard K. Ogden Jr., Jerame Hill, Sam Abdelghany

Pharmacy Posters

No abstract provided.


Decreasing Unnecessary Pharmacy Cost In The Cath Lab, Scott M. Scepaniak, Kristi Patterson Jan 2018

Decreasing Unnecessary Pharmacy Cost In The Cath Lab, Scott M. Scepaniak, Kristi Patterson

Nursing Posters

AngioMax is a single dose heparin alternative introduced in 2002 that is used in cardiac patients undergoing percutaneous intervention (PCI). Bivalirudin costs $377 per dose; heparin is less than $15 per dose. Noting practice variations, the Cath Lab set out to eliminate unnecessary pharmacy cost for PCI patients by:

  • Using current literature to inform clinical care
  • Standardizing practice
  • Using data to track and guide implementation


2016 Touro College Of Pharmacy Senior Yearbook, College Of Pharmacy Apr 2016

2016 Touro College Of Pharmacy Senior Yearbook, College Of Pharmacy

Touro Yearbooks

2016 College of Pharmacy Senior Yearbook


Purchasing Pharmaceuticals (Health, Nutrition And Population (Hnp) Discussion Paper), Ulrika Enemark, Anita Alban, Enrique Seoane-Vazquez Sep 2004

Purchasing Pharmaceuticals (Health, Nutrition And Population (Hnp) Discussion Paper), Ulrika Enemark, Anita Alban, Enrique Seoane-Vazquez

Pharmacy Faculty Books and Book Chapters

This paper discusses the purchasing of pharmaceuticals as a key component of costeffective and equitable healthcare delivery. Pharmaceuticals account for a high, sometimes the dominant share of health expenditures in developing countries, but the desired health outcomes can only be achieved if the adequate medicines reach the right people and are used in the correct way. This requires purchasing arrangements that take into account the information asymmetry between patients and providers, ensure selection of effective, safe and affordable medicines and set economic incentives in a way that encourages rational drug use. The organizational and institutional frameworks define the roles of …